Nebenwirkungen · Ponvory
Ponvory 2 mg film-coated tablets Ponvory 3 mg film-coated tablets Ponvory 4 mg film-coated tablets Ponvory 5 mg film-coated tablets Ponvory 6 mg film-coated tablets Ponvory 7 mg film-coated tablets Ponvory 8 mg film-coated tablets Ponvory 9 mg film-coated tablets Ponvory 10 mg film-coated tablets Ponvory 20 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 15
HOS-144799 · Präparat HOS-099260
Infections In the Phase 3 OPTIMUM study (see section 5.1), the overall rate of infections was comparable between the ponesimod-treated patients and those receiving teriflunomide 14 mg (54.2% vs 52.1% respectively). Nasopharyngitis and viral infections were more common in ponesimod-treated patients. Serious or severe infections occurred at a rate of 1.6% in ponesimod-treated patients compared to 0.9% of patients receiving teriflunomide 14 mg.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-10T12:00:00Z · SHA-256 22aeeb9332cb21ba49be6dac5aee38e9c86e8cc3c44811970b33408e3fed5e74 · Passage e4a66a147b0ec22454cdbaaa5101c73c3af80b1c84b4561fdef8d1241fb4faec · Zeichen 5198–5643 im Abschnitt